Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Koen de Gans

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 21, 2023
Comparative effectiveness in multiple sclerosis: A methodological comparisonIzanne Roos, Ibrahima Diouf, Sifat Sharmin, et al.
NPJ Digital Medicine|July 24, 2025
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical dataAshkan Pirmani, Edward De Brouwer, Ádám Arany, et al.
The Lancet. Neurology|May 19, 2024
Safety and efficacy of active blood-pressure reduction to the recommended thresholds for intravenous thrombolysis in patients with acute ischaemic stroke in the Netherlands (TRUTH): a prospective, observational, cluster-based, parallel-group studyThomas P Zonneveld, Sarah E Vermeer, Erik W van Zwet, et al.
Journal of Neurology|April 19, 2026
Predicting disease progression in multiple sclerosis with clinically accessible information and technologyTom A N Fuchs, Menno M Schoonheim, Eva M M Strijbis, et al.
Neurology|August 17, 2022
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple SclerosisIzanne Roos, Charles Malpas, Emmanuelle Leray, et al.
European Journal of Neurology|January 24, 2023
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosisIbrahima Diouf, Charles B Malpas, Sifat Sharmin, et al.
Journal of Neurology|February 3, 2026
Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registryAmira Souissi, Francesco Patti, Tim Spelman, et al.
Brain : a Journal of Neurology|June 27, 2023
The risk of secondary progressive multiple sclerosis is geographically determined but modifiableSifat Sharmin, Izanne Roos, Steve Simpson-Yap, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 28, 2023
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosisCyrus Daruwalla, Vahid Shaygannejad, Serkan Ozakbas, et al.
JAMA Neurology|April 14, 2025
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple SclerosisJannis Müller, Sifat Sharmin, Johannes Lorscheider, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 21, 2023
Comparative effectiveness in multiple sclerosis: A methodological comparisonIzanne Roos, Ibrahima Diouf, Sifat Sharmin, et al.
NPJ Digital Medicine|July 24, 2025
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical dataAshkan Pirmani, Edward De Brouwer, Ádám Arany, et al.
The Lancet. Neurology|May 19, 2024
Safety and efficacy of active blood-pressure reduction to the recommended thresholds for intravenous thrombolysis in patients with acute ischaemic stroke in the Netherlands (TRUTH): a prospective, observational, cluster-based, parallel-group studyThomas P Zonneveld, Sarah E Vermeer, Erik W van Zwet, et al.
Journal of Neurology|April 19, 2026
Predicting disease progression in multiple sclerosis with clinically accessible information and technologyTom A N Fuchs, Menno M Schoonheim, Eva M M Strijbis, et al.
Neurology|August 17, 2022
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple SclerosisIzanne Roos, Charles Malpas, Emmanuelle Leray, et al.
European Journal of Neurology|January 24, 2023
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosisIbrahima Diouf, Charles B Malpas, Sifat Sharmin, et al.
Journal of Neurology|February 3, 2026
Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registryAmira Souissi, Francesco Patti, Tim Spelman, et al.
Brain : a Journal of Neurology|June 27, 2023
The risk of secondary progressive multiple sclerosis is geographically determined but modifiableSifat Sharmin, Izanne Roos, Steve Simpson-Yap, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 28, 2023
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosisCyrus Daruwalla, Vahid Shaygannejad, Serkan Ozakbas, et al.
JAMA Neurology|April 14, 2025
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple SclerosisJannis Müller, Sifat Sharmin, Johannes Lorscheider, et al.
Pageof 3